The multifaceted effect of PB1-F2 specific antibodies on influenza A virus infection

Virology

Volumn 447, Issue 1-3, 2013, Pages 1-8

  Kosik I ^a   Krejnusova I ^a   Praznovska M ^a   Russ, G ^a  

^a INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

Antibodies; DNA vaccination; Humoral immunity; Immunogenicity; Influenza; PB1 F2

Indexed keywords

DNA VACCINE; INFLUENZA VACCINE; MONOCLONAL ANTIBODY; PB1 F2 ANTIBODY; PB1 F2 PROTEIN; PLASMID DNA; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS PROTEIN;

ACTIVE IMMUNIZATION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; DISEASE COURSE; FEMALE; HUMORAL IMMUNITY; IN VIVO STUDY; INFLUENZA A; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANTIBODIES; DNA VACCINATION; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA; PB1-F2;

ANIMALS; ANTIBODIES, VIRAL; BODY WEIGHT; FEMALE; IMMUNIZATION; INFLUENZA VACCINES; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; VIRAL PROTEINS;

EID: 84884337399     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.08.022     Document Type: Article

References (33)

1. 2 influenza A virus PB1-F2 map to amino acid residues 62, 75, 79, and 82. J. Virol. 2011, 85(23):12324-12333.
2. Birch-Machin I., Rowan A., Pick J., Mumford J., Binns M. Expression of the nonstructural protein NS1 of equine influenza A virus: detection of anti-NS1 antibody in post infection equine sera. J. Virol. Methods 1997, 65(2):255-263.
3. Bode C., Zhao G., Steinhagen F., Kinjo T., Klinman D.M. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines 2011, 10(4):499-511.
4. Charo J., Lindencrona J.A., Carlson L.M., Hinkula J., Kiessling R. Protective efficacy of a DNA influenza virus vaccine is markedly increased by the coadministration of a Schiff base-forming drug. J. Virol. 2004, 78(20):11321-11326.
5. Chen C.J., Chen G.W., Wang C.H., Huang C.H., Wang Y.C., Shih S.R. Differential localization and function of PB1-F2 derived from different strains of influenza A virus. J. Virol. 2010, 84(19):10051-10062.
6. Chen W., Calvo P.A., Malide D., Gibbs J., Schubert U., Bacik I., Basta S., O'Neill R., Schickli J., Palese P., Henklein P., Bennink J.R., Yewdell J.W. A novel influenza A virus mitochondrial protein that induces cell death. Nat. Med. 2001, 7(12):1306-1312.
7. Choi S.Y., Suh Y.S., Cho J.H., Jin H.T., Chang J., Sung Y.C. Enhancement of DNA Vaccine-induced immune responses by influenza virus NP gene. Immune Netw 2009, 9(5):169-178.
8. Coleman J.R. The PB1-F2 protein of Influenza A virus: increasing pathogenicity by disrupting alveolar macrophages. J. Virol 2007, 4:9.
9. de Wit E., Kawaoka Y., de Jong M.D., Fouchier R.A. Pathogenicity of highly pathogenic avian influenza virus in mammals. Vaccine 2008, 26(Suppl 4):D54-D58.
10. Henkel M., Mitzner D., Henklein P., Meyer-Almes F.J., Moroni A., Difrancesco M.L., Henkes L.M., Kreim M., Kast S.M., Schubert U., Thiel G. The proapoptotic influenza A virus protein PB1-F2 forms a nonselective ion channel. PLoS One 2010, 5(6):e11112.
11. Ilyinskii P.O., Meriin A.B., Gabai V.L., Zhirnov O.P., Thoidis G., Shneider A.M. Prime-boost vaccination with a combination of proteosome-degradable and wild-type forms of two influenza proteins leads to augmented CTL response. Vaccine 2008, 26(18):2177-2185.
12. Khurana S., Suguitan A.L., Rivera Y., Simmons C.P., Lanzavecchia A., Sallusto F., Manischewitz J., King L.R., Subbarao K., Golding H. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med. 2009, 6(4):e1000049.
13. Kolaskar A.S., Tongaonkar P.C. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 1990, 276(1-2):172-174.
14. Kosik I., Holly J., Russ G. PB1-F2 expedition from the whole protein through the domain to aa residue function. Acta Virol. 2013, 57(2):138-148.
15. Kosik I., Krejnusova I., Praznovska M., Polakova K., Russ G. A DNA vaccine expressing PB1 protein of influenza A virus protects mice against virus infection. Arch. Virol. 2012, 157(5):811-817.
16. Krejnusova I., Gocnikova H., Bystricka M., Blaskovicova H., Polakova K., Yewdell J., Bennink J., Russ G. Antibodies to PB1-F2 protein are induced in response to influenza A virus infection. Arch. Virol. 2009, 154(10):1599-1604.
17. 8+ T cell response to cognate viral peptides. Proc. Natl. Acad. Sci. U S A. 2008, 105(6):2034-2039.
18. McAuley J.L., Hornung F., Boyd K.L., Smith A.M., McKeon R., Bennink J., Yewdell J.W., McCullers J.A. Expression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host Microbe 2007, 2(4):240-249.
19. McAuley J.L., Chipuk J.E., Boyd K.L., Van De Velde N., Green D.R., McCullers J.A. PB1-F2 proteins from H5N1 and 20 century pandemic influenza viruses cause immunopathology. PLoS Pathog. 2010, 6(7):e1001014.
20. McAuley J.L., Chipuk J.E., Boyd K.L., Van de Velde N., Green D.R., McCullers J.A. PB1-F2 proteins from H5N1 and 20(th) century pandemic influenza viruses cause immunopathology. PLoS Pathog. 2010, 6:7.
21. Morens D.M., Taubenberger J.K., Fauci A.S. The 2009 H1N1 pandemic influenza virus: what next?. MBio 2010, 1:4.
22. Muramoto Y., Noda T., Kawakami E., Akkina R., Kawaoka Y. Identification of novel influenza A virus proteins translated from PA mRNA. J. Virol. 2013, 87(5):2455-2462.
23. Roder R., Bruns K., Sharma A., Eissmann A., Hahn F., Studtrucker N., Fossen T., Wray V., Henklein P., Schubert U. Synthesis of full length PB1-F2 influenza A virus proteins from 'Spanish flu' and 'bird flu'. J. Pept. Sci. 2008, 14(8):954-962.
24. Shen J., Niu J. Epidemiologic parameters and evaluation of control measure for 2009 novel influenza a (H1N1) in Xiamen, Fujian Province, China. J. Virol. 2012, 9:20.
25. Shi M., Jagger B.W., Wise H.M., Digard P., Holmes E.C., Taubenberger J.K. Evolutionary conservation of the PA-X open reading frame in segment 3 of influenza A virus. J. Virol. 2012, 86(22):12411-12413.
26. Smahel M., Polakova I., Sobotkova E., Vajdova E. Systemic administration of CpG oligodeoxynucleotide and levamisole as adjuvants for gene-gun-delivered antitumor DNA vaccines. Clin. Dev. Immunol. 2011, 2011:176759.
27. Stohr K. Preventing and treating influenza. BMJ 2003, 326(7401):1223-1224.
28. Taubenberger J.K., Morens D.M. 1918 Influenza: the mother of all pandemics. Emerg. Infect. Dis. 2006, 12(1):15-22.
29. Tkacova M., Vareckova E., Baker I.C., Love J.M., Ziegler T. Evaluation of monoclonal antibodies for subtyping of currently circulating human type A influenza viruses. J. Clin. Microbiol. 1997, 35(5):1196-1198.
30. Vareckova E., Betakova T., Mucha V., Solarikova L., Kostolansky F., Waris M., Russ G. Preparation of monoclonal antibodies for the diagnosis of influenza A infection using different immunization protocols. J. Immunol. Methods 1995, 180(1):107-116.
31. Yamada H., Chounan R., Higashi Y., Kurihara N., Kido H. Mitochondrial targeting sequence of the influenza A virus PB1-F2 protein and its function in mitochondria. FEBS Lett. 2004, 578(3):331-336.
32. Zamarin D., Ortigoza M.B., Palese P. Influenza A virus PB1-F2 protein contributes to viral pathogenesis in mice. J. Virol. 2006, 80(16):7976-7983.
33. Zell R., Krumbholz A., Eitner A., Krieg R., Halbhuber K.J., Wutzler P. Prevalence of PB1-F2 of influenza A viruses. J. Gen. Virol. 2007, 88(Pt 2):536-546.